Related Experiment Video

Updated: Dec 22, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure

Yaniel Castro-Torres1, Richard E Katholi2

  • 1Servicio de Cardiología, Hospital Universitario Celestino Hernández Robau, Santa Clara, Villa Clara, Cuba.

Current Cardiology Reviews
|May 1, 2020
PubMed

Insights

New heart failure (HF) treatments are under investigation, targeting novel mechanisms to improve patient outcomes. This review explores emerging drugs and their potential clinical implementation for heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Translational Medicine

Background:

  • Heart failure (HF) is a major global health challenge with significant morbidity and mortality.
  • Current treatments offer limited improvement for many patients, necessitating novel therapeutic strategies.
  • Recent approvals like sacubitril/valsartan offer new hope for specific HF populations.

Purpose of the Study:

  • To review the landscape of drugs currently under investigation for treating heart failure.
  • To explore the diverse novel mechanisms targeted by these emerging therapies.
  • To provide perspectives on the future implementation of these investigational drugs into clinical practice.

Main Methods:

  • Comprehensive literature review of preclinical and clinical studies.
  • Analysis of drugs targeting novel pathways in heart failure.
  • Synthesis of information on investigational drug mechanisms and potential clinical utility.

Main Results:

  • Multiple novel drug classes are in development for heart failure.
  • Investigational mechanisms include vasoactive peptides, anti-inflammatory agents, natriuretic peptides, and others.
  • Emerging therapies target diverse pathways such as the neuregulin-1/ErbB signaling and myocardial receptors.

Conclusions:

  • A range of promising new drugs are being investigated for heart failure treatment.
  • These agents target innovative mechanisms beyond current therapeutic paradigms.
  • Successful translation of these drugs could significantly alter the management and prognosis of heart failure patients.

Keywords:
Heart failuredrugs for HFheart failure managementheart failure preserved ejection fractionheart failure reduced ejection fractionheart failure treatment

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.9K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
810
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
156
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
674
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
728
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
182